Gerardo Cazarez-Navarro , Ivan Hernández-Cañaveral , Ana Gabriela Colima-Fausto , Jaime Palomares-Marín , Karel Licona-Lasteros , Ana Laura Pereira-Suarez , Sergio Yair Rodríguez-Preciado
{"title":"Analysis of the c.1135G > A, c.1993A > G, c.2059T > C TAP2 gene variants and their relationship with latent tuberculosis infection in Mexico","authors":"Gerardo Cazarez-Navarro , Ivan Hernández-Cañaveral , Ana Gabriela Colima-Fausto , Jaime Palomares-Marín , Karel Licona-Lasteros , Ana Laura Pereira-Suarez , Sergio Yair Rodríguez-Preciado","doi":"10.1016/j.jctube.2024.100501","DOIUrl":null,"url":null,"abstract":"<div><div>Tuberculosis (TB) is a worldwide public health problem with 10.6 million people falling ill and 1.5 million deaths every year. Latent tuberculosis infection (LTBI) is a condition in which an individual has been infected with <em>Mycobacterium tuberculosis</em> (<em>Mtb</em>) but does not show clinical signs and symptoms. The transporter associated with antigen processing (TAP2) protein plays a fundamental role in the immune response promoting the clearance of intracellular pathogens, such as <em>Mtb</em>. Our study aimed to determine the association between c.1135G > A (rs1800454), c.1993A > G (rs241447) and c.2059 T > C (rs241448) <em>TAP2</em> gene variants with LTBI susceptibility. In this case-control study, 180 individuals (90 were LTBI-positive and 90 were controls) from shelters were analyzed. Genotyping of the polymorphisms was performed using the Applied Biosystems Step One Thermal Cycler Real-Time PCR allelic discrimination technology. The haplotypic analyses were performed with the Arlequin 3.5 software. The G allele (OR = 1.732, CI = 1.125–2.667, <em>p</em> = 0.012) and AG genotype of the c.1993A > G variant (<em>p</em>=<0.001) were associated with susceptibility to LTBI (<em>p</em>=<0.001), as well as the GAT, AAT, AAC, AGT haplotypes (<em>p</em>=<0.001). The c.1135G > A and c.2059 T > C variants were not associated with LTBI risk.</div></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"37 ","pages":"Article 100501"},"PeriodicalIF":1.9000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405579424000883","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Tuberculosis (TB) is a worldwide public health problem with 10.6 million people falling ill and 1.5 million deaths every year. Latent tuberculosis infection (LTBI) is a condition in which an individual has been infected with Mycobacterium tuberculosis (Mtb) but does not show clinical signs and symptoms. The transporter associated with antigen processing (TAP2) protein plays a fundamental role in the immune response promoting the clearance of intracellular pathogens, such as Mtb. Our study aimed to determine the association between c.1135G > A (rs1800454), c.1993A > G (rs241447) and c.2059 T > C (rs241448) TAP2 gene variants with LTBI susceptibility. In this case-control study, 180 individuals (90 were LTBI-positive and 90 were controls) from shelters were analyzed. Genotyping of the polymorphisms was performed using the Applied Biosystems Step One Thermal Cycler Real-Time PCR allelic discrimination technology. The haplotypic analyses were performed with the Arlequin 3.5 software. The G allele (OR = 1.732, CI = 1.125–2.667, p = 0.012) and AG genotype of the c.1993A > G variant (p=<0.001) were associated with susceptibility to LTBI (p=<0.001), as well as the GAT, AAT, AAC, AGT haplotypes (p=<0.001). The c.1135G > A and c.2059 T > C variants were not associated with LTBI risk.
期刊介绍:
Journal of Clinical Tuberculosis and Mycobacterial Diseases aims to provide a forum for clinically relevant articles on all aspects of tuberculosis and other mycobacterial infections, including (but not limited to) epidemiology, clinical investigation, transmission, diagnosis, treatment, drug-resistance and public policy, and encourages the submission of clinical studies, thematic reviews and case reports. Journal of Clinical Tuberculosis and Mycobacterial Diseases is an Open Access publication.